EXHIBIT 10.35 THIS DEED is made the 12th day of September 2001. BETWEEN TIBOTEC-VIRCO N.V. whose registered address is at Intercity Business Park, Gen. De Wittelen L11B , 2800 Mechelen, Belgium (hereinafter referred to as "TVNV"); and VIRCO UK LIMITED...Visible Genetics Inc • June 14th, 2002 • In vitro & in vivo diagnostic substances • England
INDENTURE Dated as of February 10, 2004 8 3/4% Senior Subordinated Notes due 2012 CROSS-REFERENCE TABLEInverness Medical Innovations Inc • March 15th, 2004 • In vitro & in vivo diagnostic substances • New York
LEASEEPIX Pharmaceuticals, Inc. • November 9th, 2006 • In vitro & in vivo diagnostic substances
RECITALSEPIX Pharmaceuticals, Inc. • November 9th, 2006 • In vitro & in vivo diagnostic substances • New Jersey
A-1International Isotopes Inc • May 15th, 1998 • In vitro & in vivo diagnostic substances
Exhibit 10.8 EMPLOYMENT AGREEMENT THIS AGREEMENT, made and entered into as of this 13th day of October, 1998, by and between Immucor, Inc., a Georgia corporation with its executive offices at 3130 Gateway Drive, Norcross, Georgia 30091 (herein...Employment Agreement • August 30th, 1999 • Immucor Inc • In vitro & in vivo diagnostic substances • Georgia
Exhibit 99.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this "AGREEMENT"), is made and entered into as of May 14, 2007, by and among Inverness Medical Innovations, Inc. a Delaware corporation (the "COMPANY"), and the purchasers...Registration Rights Agreement • May 15th, 2007 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
i) Kay is eligible to receive a cash performance bonus, to be paid each year at the same time bonuses are generally paid to other senior executives of the Company for the relevant fiscal year (but not later than April 30) of up to 35% of Kay's Base...Employment Agreement • March 29th, 2002 • Quidel Corp /De/ • In vitro & in vivo diagnostic substances • California
EXHIBIT 10.31Stock Purchase Agreement • February 9th, 2005 • Meridian Bioscience Inc • In vitro & in vivo diagnostic substances • Ohio
INDENTUREIndenture • December 2nd, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • New York
Exhibit 10.17 APPENDIX A TO PARTICIPATION AGREEMENTParticipation Agreement • April 1st, 2002 • Human Genome Sciences Inc • In vitro & in vivo diagnostic substances
LEASE AGREEMENT THIS LEASE AGREEMENT, made on June 24, 2005, by and between HEMAGEN PROPERTIES, LLC, a Maryland limited liability company (hereinafter called "Landlord"), and HEMAGEN DIAGNOSTICS, INC., a Delaware corporation (hereinafter called...Lease Agreement • August 15th, 2005 • Hemagen Diagnostics Inc • In vitro & in vivo diagnostic substances • Maryland
EXHIBIT 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this "Agreement") is made and entered into as of January 10, 2005 (the "Effective Date"), by and between SCOLR Pharma, Inc., a Delaware corporation ("the Company"), and Alan M. Mitchel...Employment Agreement • January 11th, 2005 • SCOLR Pharma, Inc. • In vitro & in vivo diagnostic substances • Washington
EXHIBIT 2Consulting Agreement • October 24th, 2002 • Caprius Inc • In vitro & in vivo diagnostic substances • Delaware
RecitalsPurchase Agreement • February 7th, 2003 • Trinity Biotech PLC • In vitro & in vivo diagnostic substances • New York
Exhibit 4.21 ------------ NEITHER THIS SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM...Synova Healthcare Group Inc • April 28th, 2006 • In vitro & in vivo diagnostic substances
COMMON STOCK PURCHASE WARRANTNymox Pharmaceutical Corp • March 22nd, 2022 • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the fifth anniversary of the Effective Date (as defined in the Purchase Agreement) (the “Termination Date”) but not thereafter, to subscribe for and purchase from Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), up to [ ] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
RECITALSVoting Agreement • April 16th, 2004 • Boston Biomedica Inc • In vitro & in vivo diagnostic substances • Delaware
PLEDGE AGREEMENT PLEDGE AGREEMENT dated as of September 24, 1998 by and between Owen A. Dempsey, an individual with an address at 21 Harris Street, Brookline, Massachusetts 02146 (the "Pledgor"), in favor of Endogen, Inc., a Massachusetts corporation,...Pledge Agreement • January 14th, 1999 • Endogen Inc • In vitro & in vivo diagnostic substances • Massachusetts
INDEX" - The Consumer Price Index (including fruits and vegetables) that is published by the Central Statistics Office (the "OFFICE"). "THE BASIC INDEX" - The Index that was published on September 15, 2004 for the month of August 2004. "LINKED"...Management Agreement • November 9th, 2006 • EPIX Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
EXHIBIT 10.6 SUBSCRIPTION AGREEMENTSubscription Agreement • September 19th, 2003 • Centrex Inc • In vitro & in vivo diagnostic substances • Oklahoma
EXHIBIT 3 STOCK PURCHASE AGREEMENT AMENDMENT NO. 1 This Stock Purchase Agreement Amendment No. 1 (this "Amendment") dated as of July 15, 2003, is entered into by and among Estate of Gordon A. Cain (the "Estate"), RCM Financial Services, L.P., a...Stock Purchase Agreement • July 18th, 2003 • McNair Robert C • In vitro & in vivo diagnostic substances • Delaware
EXHIBIT 10.1 ------------------------------------------------------------------ -------------- LOAN AND SECURITY AGREEMENT --------------------------- -------- ------------------------------------------------------------------------Loan and Security Agreement • January 13th, 2000 • Dynagen Inc • In vitro & in vivo diagnostic substances • Massachusetts
EXHIBIT 10.3 ALPHA INNOTECH CORPORATION EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the "AGREEMENT") is made and entered into as of May 11, 2001 by and between Alpha Innotech Corporation, a California corporation (the "COMPANY") and Haseeb...Employment Agreement • October 7th, 2005 • Alpha Innotech Corp • In vitro & in vivo diagnostic substances • California
DISTRIBUTION AGREEMENT ---------------------- THIS AGREEMENT, made as of this 8th day of April, 1998 by and between Endogen Inc., a Massachusetts corporation having its principal place of business at 30 Commerce Way, Woburn, MA 01801-1059 (hereinafter...Distribution Agreement • August 28th, 1998 • Endogen Inc • In vitro & in vivo diagnostic substances • Massachusetts
Exhibit 7 INVERNESS MEDICAL TECHNOLOGY, INC. AMENDED AND RESTATED 2000 STOCK OPTION AND GRANT PLAN INCENTIVE STOCK OPTION AGREEMENT 150,000 Shares AWARDED FEBRUARY 12, 2001 ------- ------------------------- Pursuant to its Amended and Restated 2000...Option Agreement • September 30th, 2002 • Zwanziger Ron • In vitro & in vivo diagnostic substances
amongAgreement and Plan of Merger • February 11th, 2003 • Osi Pharmaceuticals Inc • In vitro & in vivo diagnostic substances • Delaware
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 22nd, 2022 • Nymox Pharmaceutical Corp • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 18, 2022, between Nymox Pharmaceutical Corporation, a company incorporated under the International Business Companies Act of the Bahamas (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
AGREEMENT AND PLAN OF MERGER by and among:Agreement and Plan of Merger • May 15th, 2007 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • Delaware
RECITALSSupplemental Indenture • May 10th, 2007 • Inverness Medical Innovations Inc • In vitro & in vivo diagnostic substances • New York
AGREEMENTStock Option Agreement • March 29th, 2002 • Quidel Corp /De/ • In vitro & in vivo diagnostic substances • California
BACKGROUNDSecurities Purchase Agreement • April 6th, 2006 • Synova Healthcare Group Inc • In vitro & in vivo diagnostic substances • Nevada
Exhibit 10.52 PURCHASE AND SALE AGREEMENT by and between PHL-OPCO, LP, a Delaware limited partnership, as Seller,Purchase and Sale Agreement • March 28th, 2001 • Medtox Scientific Inc • In vitro & in vivo diagnostic substances • Minnesota
ARTICLE I THE LOAN --------Loan Agreement • March 26th, 2004 • Aspenbio Inc • In vitro & in vivo diagnostic substances • Colorado
AGREEMENT JOINT FILING OF SCHEDULE 13D The undersigned hereby agrees to jointly prepare and file with regulatory authorities a Schedule 13D and any future amendments thereto reporting each of the undersigned's ownership of securities of Neoprobe...Agreement • March 8th, 2000 • Aries Financial Services Inc • In vitro & in vivo diagnostic substances
The undersigned hereby agrees to jointly prepare and file with regulatory authorities a Schedule 13D and any future amendments thereto reporting each of the undersigned's ownership of securities of Neoprobe Corp., and hereby affirm that such Schedule 13D is being filed on behalf of each of the undersigned.
